The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 26, 2023
Filed:
Dec. 17, 2018
Centro DE Inmunología Molecular, Havana, CU;
Circe Mesa Pardillo, Havana, CU;
Liliana Oliver Ríos, Havana, CU;
Rydell Alvarez Arzola, Havana, CU;
Vladimir Peña Sánchez, Havana, CU;
Luis Enrique Fernández Molina, Havana, CU;
Anet Valdés Zayas, Havana, CU;
Maura Lisett Rábade Chediak, Havana, CU;
Lena Aguiar García, Prov. Artemisa, CU;
Lourdes Hernández de La Rosa, Havana, CU;
Audry Fernández Gómez, Havana, CU;
Leslie Pérez Ruíz, Plaza de la Revolución, CU;
Camilo Rodríguez Rodríguez, Plaza de la Revolución, CU;
Elias Antonio Gracia Medina, Havana, CU;
María Caridad Rubio Hernández, Havana, CU;
Orlando Valdés Guerrero, Havana, CU;
Idelmis Curbelo Haredia, Havana, CU;
Centro de Inmunología Molecular, Havana, CU;
Abstract
The present invention describes a pharmaceutical composition whose active ingredient includes conjugates of membrane vesicles ofand the GM3 ganglioside in a conjugation ratio in excess of proteins, has particular characteristics of size, surface charge and a morphology associated with nano-particulate systems that give it advantageous properties as an immunomodulator, because it induces a convenient and significant reduction of myeloid-derived suppressor cells that has an impact on the response of lymphocytes and on the survival of patients with tumors. The invention further discloses the use of the pharmaceutical composition disclosed in the treatment of cancer, particularly those cancers where the myeloid-derived suppressor cells (MDSCs) are high; as well as a method of treatment with said composition in cancer patients and a method to select those who will receive said treatment.